September 21, 2017 9:44 PM ET


Company Overview of TauRx Pharmaceuticals Ltd.

Company Overview

TauRx Pharmaceuticals Ltd. discovers and develops treatments and diagnostics for Alzheimer’s disease and other neurodegenerative diseases. Its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer’s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. TauRx Pharmaceuticals Ltd. was founded in 2002 and is based in Singapore with a research facility in Aberdeen, Scotland.

3, Shenton Way


Shenton House

Singapore,  068805


Founded in 2002


33 615 05 6686

Key Executives for TauRx Pharmaceuticals Ltd.

Co-Founder, Chairman and Chief Executive Officer
Finance Director
Chief Operating Officer and Chief Business Officer
Managing Director and Director
Chief Medical Officer
Compensation as of Fiscal Year 2017.

TauRx Pharmaceuticals Ltd. Key Developments

TauRx Pharmaceuticals Ltd. Presents at The 14th Annual BIO Asia International Conference, Mar-14-2017

TauRx Pharmaceuticals Ltd. Presents at The 14th Annual BIO Asia International Conference, Mar-14-2017 . Venue: Grand Hyatt Tokyo, Tokyo, Japan. Speakers: Timothy Earle, Chief Operating Officer and Chief Business Officer.

TauRx Therapeutics Ltd Reports First Phase 3 Results for LMTX

TauRx Therapeutics Ltd. announced Phase 3 clinical trial results that show treatment with LMTX®, the company's novel tau aggregation inhibitor, had a marked beneficial effect on key measures of Alzheimer's disease in patients with mild or moderate forms of the disease. While the TRx-237-015 study in 891 subjects failed to meet its co-primary endpoints, clinically meaningful and statistically significant reductions in the rate of disease progression were observed across three key measures in patients who were treated with LMTX® as their only Alzheimer's disease medication. These three key measures comprised a cognitive assessment (ADAS-Cog), a functional assessment (ADCS-ADL) and an assessment of the level of brain atrophy (lateral ventricular volume, LVV, as measured by MRI). An abstract of the results will be presented during an open session at the 2016 Alzheimer's Association International Conference (AAIC) in Toronto, Canada this afternoon by Dr. Serge Gauthier, CM, MD, FRCPC, Director of the Alzheimer's Disease Research Unit, McGill University, Canada. The same efficacy findings were not seen in study patients who took LMTX® in combination with other standard Alzheimer's treatments. Since these patients formed the substantial majority of those recruited to the trial, the treatment benefits seen in those taking LMTX® as monotherapy could not be seen when all patients taking LMTX® were pooled in the primary analysis model. Although this prevented the study from achieving an overall statistical significance in the pooled analysis, the primary analysis model showed a highly significant effect of treatment in the patients taking LMTX® as monotherapy. This treatment benefit was confirmed in a prespecified supportive analysis of all of the study's primary and secondary outcomes. This is the first treatment in which a clinical effect has been supported by evidence in delay of progression in brain atrophy shown by MRI scans. An initial analysis of data from the second of TauRx's two Phase 3 trials in Alzheimer's disease, study TRx-237-005 undertaken in 800 patients with the mild form of the disease, confirms the findings of study TRx-237-015 and supports the potential of LMTX® as monotherapy. The results from this study are expected to be published and presented later in 2016.

TauRx Pharmaceuticals Ltd. Presents at The 23rd Annual Future Leaders in the Biotech Industry conference, Mar-11-2016 08:30 AM

TauRx Pharmaceuticals Ltd. Presents at The 23rd Annual Future Leaders in the Biotech Industry conference, Mar-11-2016 08:30 AM. Venue: Millennium Broadway Hotel & Conference Center, 145 West 44th Street, Room 508, New York, New York, United States.

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TauRx Pharmaceuticals Ltd., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at